Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - CRISPR Gene Editing
Market Segmentation
Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara Bio
Key Questions Answered in this Report:
The development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry. The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineering. However, there are several limitations, which need consideration before clinical applications. Further, many researchers are working on the limitations of CRISPR gene editing technology for better results. The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.
The growth is attributed to the increasing demand in the food industry for better products with improved quality and nutrient enrichment and the pharmaceutical industry for targeted treatment for various diseases. Further, the continued significant investments by healthcare companies to meet the industry demand and growing prominence for the gene therapy procedures with less turnaround time are the prominent factors propelling the growth of the global CRISPR gene editing market.
Research organizations, pharmaceutical and biotechnology industries, and institutes are looking for more efficient genome editing technologies to increase the specificity and cost-effectiveness, also to reduce turnaround time and human errors. Further, the evolution of genome editing technologies has enabled wide range of applications in various fields, such as industrial biotech and agricultural research. These advanced methods are simple, super-efficient, cost-effective, provide multiplexing, and high throughput capabilities. The increase in the geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for CRISPR gene editing market.
Furthermore, the companies are investing huge amounts in the research and development of CRISPR gene editing products, and gene therapies. The clinical trial landscape of various genetic and chronic diseases has been on the rise in recent years, and this will fuel the CRISPR gene editing market in the future.
Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CRISPR gene editing. Due to the diverse product portfolio and intense market penetration, Merck KGaA, and Thermo Fisher Scientific Inc. have been the pioneers in this field and have been the major competitors in this market. The other major contributors of the market include companies such as Integrated DNA Technologies (IDT), Genscript Biotech Corporation, Takara Bio Inc, Agilent Technologies, Inc., and New England Biolabs, Inc.
Based on region, North America holds the largest share of CRISPR gene editing market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Market Report Coverage - CRISPR Gene Editing
Market Segmentation
- Product Type – CRISPR Products: Kits and Enzymes (Vector-Based Cas9, and DNA-Free Cas9), Libraries, Design Tools, Antibodies, and Other Products (CRISPR/Cas9 plasmids, CRISPR Controls, and CRISPR RNAs); CRISPR Services: gRNA Design and Vector Construction, Cell Line and Engineering, Screening Services, and Other Services (Mediated Transcriptome Editing, and Epigenome Editing Services)
- Application – Agricultural, Biomedical (Gene Therapy, Drug Discovery, And Diagnostics), Industrial, and Other Applications [Genetically Modified Foods (GM Foods), Biofuel, And Animal (Livestock) Breeding]
- End-User - Academic Institutes and Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), and Pharmaceutical and Biopharmaceutical Companies
- North America – U.S., Canada
- Europe – Germany, France, Italy, U.K., Spain, Switzerland, and Rest-of-Europe
- Asia-Pacific – China, Japan, India, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
- Latin America – Brazil, Mexico, and Rest-of-the-Latin America
- Rest-of-the-World
- Prevalence of Genetic Disorders and Use of Genome Editing
- Government and Private Funding
- Technology Advancement in CRISPR Gene Editing
- CRISPR Gene Editing: Off Target Effects and Delivery
- Ethical Concerns and Implications with Respect to Human Genome Editing
- Expanding Gene and Cell Therapy Area
- CRISPR Gene Editing Scope in Agriculture
Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara Bio
Key Questions Answered in this Report:
- What is CRISPR gene editing?
- What is the timeline for the development of CRISPR technology?
- How did the CRISPR gene editing market evolve, and what is its scope in the future?
- What are the major market drivers, restraints, and opportunities in the global CRISPR gene editing market?
- What are the key developmental strategies that are being implemented by the key players to sustain this market?
- What is the patent landscape of this market? What will be the impact of patent expiry on this market?
- What is the impact of COVID-19 on this market?
- What are the guidelines implemented by different government bodies to regulate the approval of CRISPR products/therapies?
- How is CRISPR gene editing being utilized for the development of therapeutics?
- How will the investments by public and private companies and government organizations affect the global CRISPR gene editing market?
- What was the market size of the leading segments and sub-segments of the global CRISPR gene editing market in 2019?
- How will the industry evolve during the forecast period 2020-2030?
- What will be the growth rate of the CRISPR gene editing market during the forecast period?
- How will each of the segments of the global CRISPR gene editing market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2030?
- Which product segment and application segment are expected to register the highest CAGR for the global CRISPR gene editing market?
- What are the major benefits of the implementation of CRISPR gene editing in different field of applications including biomedical research, agricultural research, industrial research, gene therapy, drug discovery, and diagnostics?
- What is the market size of the CRISPR gene editing market in different countries of the world?
- Which geographical region is expected to contribute to the highest sales of CRISPR gene editing market?
- What are the reimbursement scenario and regulatory structure for the CRISPR gene editing market in different regions?
- What are the key strategies incorporated by the players of global CRISPR gene editing market to sustain the competition and retain their supremacy?
The development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry. The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineering. However, there are several limitations, which need consideration before clinical applications. Further, many researchers are working on the limitations of CRISPR gene editing technology for better results. The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.
The growth is attributed to the increasing demand in the food industry for better products with improved quality and nutrient enrichment and the pharmaceutical industry for targeted treatment for various diseases. Further, the continued significant investments by healthcare companies to meet the industry demand and growing prominence for the gene therapy procedures with less turnaround time are the prominent factors propelling the growth of the global CRISPR gene editing market.
Research organizations, pharmaceutical and biotechnology industries, and institutes are looking for more efficient genome editing technologies to increase the specificity and cost-effectiveness, also to reduce turnaround time and human errors. Further, the evolution of genome editing technologies has enabled wide range of applications in various fields, such as industrial biotech and agricultural research. These advanced methods are simple, super-efficient, cost-effective, provide multiplexing, and high throughput capabilities. The increase in the geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for CRISPR gene editing market.
Furthermore, the companies are investing huge amounts in the research and development of CRISPR gene editing products, and gene therapies. The clinical trial landscape of various genetic and chronic diseases has been on the rise in recent years, and this will fuel the CRISPR gene editing market in the future.
Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CRISPR gene editing. Due to the diverse product portfolio and intense market penetration, Merck KGaA, and Thermo Fisher Scientific Inc. have been the pioneers in this field and have been the major competitors in this market. The other major contributors of the market include companies such as Integrated DNA Technologies (IDT), Genscript Biotech Corporation, Takara Bio Inc, Agilent Technologies, Inc., and New England Biolabs, Inc.
Based on region, North America holds the largest share of CRISPR gene editing market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
EXECUTIVE SUMMARY
1 TECHNOLOGY DEFINITION
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2 RESEARCH SCOPE
2.1 Key Questions Answered in the Report
2.2 Target Audience
3 RESEARCH METHODOLOGY
3.1 CRISPR Gene Editing: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Introduction
4.2 CRISPR Gene Editing Market Approach
4.3 Milestones in CRISPR Gene Editing
4.4 CRISPR Gene Editing: Delivery Systems
4.5 CRISPR Technology: A Potential Tool for Gene Editing
4.6 CRISPR Gene Editing Current Scenario
4.7 CRISPR Gene Editing Market: Future Potential Application Areas
5 GLOBAL CRISPR GENE EDITING MARKET, $MILLION, 2020-2030
5.1 Pipeline Analysis
5.2 CRISPR Gene Editing Market and Growth Potential, 2020-2030
5.3 Impact of COVID-19 on CRISPR Gene Editing Market
5.3.1 Impact of COVID-19 on Global CRISPR Gene Editing Market Growth Rate
5.3.1. Impact on CRISPR Gene Editing Companies
5.3.2 Clinical Trial Disruptions and Resumptions
5.3.3 Application of CRISPR Gene Editing in COVID-19
6 MARKET DYNAMICS
6.1 Impact Analysis
6.2 Market Drivers
6.2.1 Prevalence of Genetic Disorders and Use of Genome Editing
6.2.2 Government and Private Funding
6.2.3 Technology Advancement in CRISPR Gene Editing
6.3 Market Restraints
6.3.1 CRISPR Gene Editing: Off Target Effects and Delivery
6.3.2 Ethical Concerns and Implications With Respect to Human Genome Editing
6.4 Market Opportunities
6.4.1 Expanding Gene and Cell Therapy Area
6.4.2 CRISPR Gene Editing Scope in Agriculture
7 INDUSTRY INSIGHTS
7.1 Introduction
7.2 Funding Scenario
7.2.1 Funding Scenario: Public Companies
7.2.2 Funding Scenario: Private Companies
7.2.3 Funding Scenario: Investments by Government Organizations
7.3 Regulatory Scenario of CRISPR Gene Editing Market
7.3.1 Overview
7.3.2 Legal Requirements and Frameworks in the U.S.
7.3.3 Clinical Trial Authorization
7.3.4 Marketing Authorization
7.3.5 USFDA Guidelines for BLA Submission
7.3.6 Post-Authorization Regulations
7.3.7 Legal Requirements and Frameworks in Europe
7.3.7.1 EMA Biologics License Application Process
7.3.7.2 Centralized Procedure
7.3.7.3 Decentralized Procedure
7.3.7.4 Mutual-Recognition Procedure
7.3.7.5 National Procedure
7.3.8 Legal Requirements and Frameworks in Asia-Pacific
7.3.9 Legal Requirements and Framework in Japan
7.3.10 Expedited Regulatory Designations Around the World
7.4 Pricing of CRISPR Gene Editing
7.5 Reimbursement of CRISPR Gene Editing
7.5.1 CRISPR Gene Editing: Insurance Coverage in the U.S.
8 CRISPR GENE EDITING PATENT LANDSCAPE
8.1 Overview
8.2 CRISPR Gene Editing Market Patent Landscape: By Application
8.3 CRISPR Gene Editing Market Patent Landscape: By Region
8.4 CRISPR Gene Editing Market Patent Landscape: By Year
9 GLOBAL CRISPR GENE EDITING MARKET (BY PRODUCT TYPE), $MILLION
9.1 Overview
9.2 CRISPR Products
9.2.1 Kits and Enzymes
9.2.1.1 Vector-Based Cas9
9.2.1.2 DNA-Free Cas9
9.2.2 Libraries
9.2.3 Design Tools
9.2.4 Antibodies
9.2.5 Other Products
9.3 CRISPR Services
9.3.1 gRNA Design and Vector Construction
9.3.2 Cell Line and Engineering
9.3.3 Screening Services
9.3.4 Other Services
10 CRISPR GENE EDITING MARKET (BY APPLICATION), $MILLION
10.1 Overview
10.2 Agriculture
10.3 Biomedical
10.3.1 Gene Therapy
10.3.2 Drug Discovery
10.3.3 Diagnostics
10.4 Industrial
10.5 Other Applications
11 GLOBAL CRISPR GENE EDITING MARKET (BY END USER)
11.1 Academic Institutions and Research Centers
11.2 Biotechnology Companies
11.3 Contract Research Organizations (CROs)
11.4 Pharmaceutical and Biopharmaceutical Companies
12 GLOBAL CRISPR GENE EDITING MARKET (BY REGION)
12.1 Introduction
12.1.1 Global CRISPR Gene Editing Market (by Region), 2019-2030
12.2 North America
12.2.1 U.S.
12.2.1.1 U.S. CRISPR Gene Editing Market (by Application), 2019-2030
12.2.2 Canada
12.2.2.1 Canada CRISPR Gene Editing Market (by Application), 2019-2030
12.3 Europe
12.3.1 U.K.
12.3.1.1 U.K. CRISPR Gene Editing Market (by Application), 2019-2030
12.3.2 Germany
12.3.2.1 Germany CRISPR Gene Editing Market (by Application), 2019-2030
12.3.3 France
12.3.3.1 France CRISPR Gene Editing Market (by Application), 2019-2030
12.3.4 Spain
12.3.4.1 Spain CRISPR Gene Editing Market (by Application), 2019-2030
12.3.5 Italy
12.3.5.1 Italy CRISPR Gene Editing Market (by Application), 2019-2030
12.3.6 Switzerland
12.3.6.1 Switzerland CRISPR Gene Editing Market (by Application), 2019-2030
12.3.7 Rest-of-Europe
12.3.7.1 Rest-of-Europe CRISPR Gene Editing Market (by Application), 2019-2030
12.4 Asia-Pacific
12.4.1 Japan
12.4.1.1 Japan CRISPR Gene Editing Market (by Application), 2019-2030
12.4.2 China
12.4.2.1 China CRISPR Gene Editing Market (by Application), 2019-2030
12.4.3 South Korea
12.4.3.1 South Korea CRISPR Gene Editing Market (by Application), 2019-2030
12.4.4 Singapore
12.4.4.1 Singapore CRISPR Gene Editing Market (by Application), 2019-2030
12.4.5 Australia
12.4.5.1 Australia CRISPR Gene Editing Market (by Application), 2019-2030
12.4.6 India
12.4.6.1 India CRISPR Gene Editing Market (by Application), 2019-2030
12.4.7 Rest-of-APAC
12.4.7.1 Rest-of-APAC CRISPR Gene Editing Market (by Application), 2019-2030
12.5 Latin America
12.5.1 Brazil
12.5.1.1 Brazil CRISPR Gene Editing Market (by Application), 2019-2030
12.5.2 Mexico
12.5.2.1 Mexico CRISPR Gene Editing Market (by Application), 2019-2030
12.5.3 Rest-of-Latin America
12.5.3.1 RoLA CRISPR Gene Editing Market (by Application), 2019-2030
12.6 Rest-of-the-World
12.6.1 RoW CRISPR Gene Editing Market (by Application), 2019-2030
13 COMPETITIVE LANDSCAPE
13.1 Key Developments and Strategies
13.1.1 Overview
13.1.1.1 Regulatory and Legal Developments
13.1.1.2 Synergistic Activities
13.1.1.3 M&A Activities
13.1.1.4 Funding Activities
13.2 Market Share Analysis
13.3 Growth Share Analysis
14 COMPANY PROFILES
14.1 Overview
14.2 Abcam, Inc.
14.2.1 Company Overview
14.2.2 Role of Abcam, Inc. in the Global CRISPR Gene Editing Market
14.2.3 Financials
14.2.4 SWOT Analysis
14.3 Applied StemCell, Inc.
14.3.1 Company Overview
14.3.2 Role of Applied StemCell, Inc. in the Global CRISPR Gene Editing Market
14.3.3 SWOT Analysis
14.4 Agilent Technologies, Inc.
14.4.1 Company Overview
14.4.2 Role of Agilent Technologies, Inc. in the Global CRISPR Gene Editing Market
14.4.3 Financials
14.4.4 R&D Expenditure, 2017-2019
14.4.5 SWOT Analysis
14.5 Cellecta, Inc.
14.5.1 Company Overview
14.5.2 Role of Cellecta, Inc. in the Global CRISPR Gene Editing Market
14.5.3 SWOT Analysis
14.6 CRISPR Therapeutics AG
14.6.1 Company Overview
14.6.2 Role of CRISPR Therapeutics AG in the Global CRISPR Gene Editing Market
14.6.3 Financials
14.6.4 R&D Expenditure, 2017-2019
14.6.5 SWOT Analysis
14.7 Thermo Fisher Scientific, Inc. INC
14.7.1 Company Overview
14.7.2 Role of Thermo Fisher Scientific, Inc. in the Global CRISPR Gene Editing Market
14.7.3 Financials
14.7.4 R&D Expenditure, 2017-2019
14.7.5 SWOT Analysis
14.8 GeneCopoeia, Inc.
14.8.1 Company Overview
14.8.2 Role of GeneCopoeia, Inc. in the Global CRISPR Gene Editing Market
14.8.3 SWOT Analysis
14.9 GeneScript Biotech Corporation
14.9.1 Company Overview
14.9.2 Role of GenScript Biotech in the Global CRISPR Gene Editing Market
14.9.3 Financials
14.9.4 SWOT Analysis
14.1 Horizon Discovery Group PLC
14.10.1 Company Overview
14.10.2 Role of Horizon Discovery Group PLC in the Global CRISPR Gene Editing Market
14.10.3 Financials
14.10.4 SWOT Analysis
14.11 Integrated DNA Technologies, Inc.
14.11.1 Company Overview
14.11.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market
14.11.3 SWOT Analysis
14.12 Merck KGaA
14.12.1 Company Overview
14.12.2 Role of Merck KGaA in the Global CRISPR Gene Editing Market
14.12.3 Financials
14.12.4 SWOT Analysis
14.13 New England Biolabs, Inc.
14.13.1 Company Overview
14.13.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market
14.13.3 SWOT Analysis
14.14 Origene Technologies, Inc.
14.14.1 Company Overview
14.14.2 Role of Origene Technologies, Inc. in the Global CRISPR Gene Editing Market
14.14.3 SWOT Analysis
14.15 Rockland Immunochemicals, Inc.
14.15.1 Company Overview
14.15.2 Role of Rockland Immunochemicals, Inc. in the Global CRISPR Gene Editing Market
14.15.3 SWOT Analysis
14.16 Synthego Corporation
14.16.1 Company Overview
14.16.2 Role of Synthego Corporation in the Global CRISPR Gene Editing Market
14.16.3 SWOT Analysis
14.17 System Biosciences LLC
14.17.1 Company Overview
14.17.2 Role of System Biosciences LLC in the Global CRISPR Gene Editing Market
14.17.3 SWOT Analysis
14.18 ToolGen, Inc.
14.18.1 Company Overview
14.18.2 Role of ToolGen, Inc. in the Global CRISPR Gene Editing Market
14.18.3 SWOT Analysis
14.19 Takara Bio
14.19.1 Company Overview
14.19.2 Role of Takara Bio in the Global CRISPR Gene Editing Market
14.19.3 Financials
14.19.4 SWOT Analysis
1 TECHNOLOGY DEFINITION
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2 RESEARCH SCOPE
2.1 Key Questions Answered in the Report
2.2 Target Audience
3 RESEARCH METHODOLOGY
3.1 CRISPR Gene Editing: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Introduction
4.2 CRISPR Gene Editing Market Approach
4.3 Milestones in CRISPR Gene Editing
4.4 CRISPR Gene Editing: Delivery Systems
4.5 CRISPR Technology: A Potential Tool for Gene Editing
4.6 CRISPR Gene Editing Current Scenario
4.7 CRISPR Gene Editing Market: Future Potential Application Areas
5 GLOBAL CRISPR GENE EDITING MARKET, $MILLION, 2020-2030
5.1 Pipeline Analysis
5.2 CRISPR Gene Editing Market and Growth Potential, 2020-2030
5.3 Impact of COVID-19 on CRISPR Gene Editing Market
5.3.1 Impact of COVID-19 on Global CRISPR Gene Editing Market Growth Rate
5.3.1. Impact on CRISPR Gene Editing Companies
5.3.2 Clinical Trial Disruptions and Resumptions
5.3.3 Application of CRISPR Gene Editing in COVID-19
6 MARKET DYNAMICS
6.1 Impact Analysis
6.2 Market Drivers
6.2.1 Prevalence of Genetic Disorders and Use of Genome Editing
6.2.2 Government and Private Funding
6.2.3 Technology Advancement in CRISPR Gene Editing
6.3 Market Restraints
6.3.1 CRISPR Gene Editing: Off Target Effects and Delivery
6.3.2 Ethical Concerns and Implications With Respect to Human Genome Editing
6.4 Market Opportunities
6.4.1 Expanding Gene and Cell Therapy Area
6.4.2 CRISPR Gene Editing Scope in Agriculture
7 INDUSTRY INSIGHTS
7.1 Introduction
7.2 Funding Scenario
7.2.1 Funding Scenario: Public Companies
7.2.2 Funding Scenario: Private Companies
7.2.3 Funding Scenario: Investments by Government Organizations
7.3 Regulatory Scenario of CRISPR Gene Editing Market
7.3.1 Overview
7.3.2 Legal Requirements and Frameworks in the U.S.
7.3.3 Clinical Trial Authorization
7.3.4 Marketing Authorization
7.3.5 USFDA Guidelines for BLA Submission
7.3.6 Post-Authorization Regulations
7.3.7 Legal Requirements and Frameworks in Europe
7.3.7.1 EMA Biologics License Application Process
7.3.7.2 Centralized Procedure
7.3.7.3 Decentralized Procedure
7.3.7.4 Mutual-Recognition Procedure
7.3.7.5 National Procedure
7.3.8 Legal Requirements and Frameworks in Asia-Pacific
7.3.9 Legal Requirements and Framework in Japan
7.3.10 Expedited Regulatory Designations Around the World
7.4 Pricing of CRISPR Gene Editing
7.5 Reimbursement of CRISPR Gene Editing
7.5.1 CRISPR Gene Editing: Insurance Coverage in the U.S.
8 CRISPR GENE EDITING PATENT LANDSCAPE
8.1 Overview
8.2 CRISPR Gene Editing Market Patent Landscape: By Application
8.3 CRISPR Gene Editing Market Patent Landscape: By Region
8.4 CRISPR Gene Editing Market Patent Landscape: By Year
9 GLOBAL CRISPR GENE EDITING MARKET (BY PRODUCT TYPE), $MILLION
9.1 Overview
9.2 CRISPR Products
9.2.1 Kits and Enzymes
9.2.1.1 Vector-Based Cas9
9.2.1.2 DNA-Free Cas9
9.2.2 Libraries
9.2.3 Design Tools
9.2.4 Antibodies
9.2.5 Other Products
9.3 CRISPR Services
9.3.1 gRNA Design and Vector Construction
9.3.2 Cell Line and Engineering
9.3.3 Screening Services
9.3.4 Other Services
10 CRISPR GENE EDITING MARKET (BY APPLICATION), $MILLION
10.1 Overview
10.2 Agriculture
10.3 Biomedical
10.3.1 Gene Therapy
10.3.2 Drug Discovery
10.3.3 Diagnostics
10.4 Industrial
10.5 Other Applications
11 GLOBAL CRISPR GENE EDITING MARKET (BY END USER)
11.1 Academic Institutions and Research Centers
11.2 Biotechnology Companies
11.3 Contract Research Organizations (CROs)
11.4 Pharmaceutical and Biopharmaceutical Companies
12 GLOBAL CRISPR GENE EDITING MARKET (BY REGION)
12.1 Introduction
12.1.1 Global CRISPR Gene Editing Market (by Region), 2019-2030
12.2 North America
12.2.1 U.S.
12.2.1.1 U.S. CRISPR Gene Editing Market (by Application), 2019-2030
12.2.2 Canada
12.2.2.1 Canada CRISPR Gene Editing Market (by Application), 2019-2030
12.3 Europe
12.3.1 U.K.
12.3.1.1 U.K. CRISPR Gene Editing Market (by Application), 2019-2030
12.3.2 Germany
12.3.2.1 Germany CRISPR Gene Editing Market (by Application), 2019-2030
12.3.3 France
12.3.3.1 France CRISPR Gene Editing Market (by Application), 2019-2030
12.3.4 Spain
12.3.4.1 Spain CRISPR Gene Editing Market (by Application), 2019-2030
12.3.5 Italy
12.3.5.1 Italy CRISPR Gene Editing Market (by Application), 2019-2030
12.3.6 Switzerland
12.3.6.1 Switzerland CRISPR Gene Editing Market (by Application), 2019-2030
12.3.7 Rest-of-Europe
12.3.7.1 Rest-of-Europe CRISPR Gene Editing Market (by Application), 2019-2030
12.4 Asia-Pacific
12.4.1 Japan
12.4.1.1 Japan CRISPR Gene Editing Market (by Application), 2019-2030
12.4.2 China
12.4.2.1 China CRISPR Gene Editing Market (by Application), 2019-2030
12.4.3 South Korea
12.4.3.1 South Korea CRISPR Gene Editing Market (by Application), 2019-2030
12.4.4 Singapore
12.4.4.1 Singapore CRISPR Gene Editing Market (by Application), 2019-2030
12.4.5 Australia
12.4.5.1 Australia CRISPR Gene Editing Market (by Application), 2019-2030
12.4.6 India
12.4.6.1 India CRISPR Gene Editing Market (by Application), 2019-2030
12.4.7 Rest-of-APAC
12.4.7.1 Rest-of-APAC CRISPR Gene Editing Market (by Application), 2019-2030
12.5 Latin America
12.5.1 Brazil
12.5.1.1 Brazil CRISPR Gene Editing Market (by Application), 2019-2030
12.5.2 Mexico
12.5.2.1 Mexico CRISPR Gene Editing Market (by Application), 2019-2030
12.5.3 Rest-of-Latin America
12.5.3.1 RoLA CRISPR Gene Editing Market (by Application), 2019-2030
12.6 Rest-of-the-World
12.6.1 RoW CRISPR Gene Editing Market (by Application), 2019-2030
13 COMPETITIVE LANDSCAPE
13.1 Key Developments and Strategies
13.1.1 Overview
13.1.1.1 Regulatory and Legal Developments
13.1.1.2 Synergistic Activities
13.1.1.3 M&A Activities
13.1.1.4 Funding Activities
13.2 Market Share Analysis
13.3 Growth Share Analysis
14 COMPANY PROFILES
14.1 Overview
14.2 Abcam, Inc.
14.2.1 Company Overview
14.2.2 Role of Abcam, Inc. in the Global CRISPR Gene Editing Market
14.2.3 Financials
14.2.4 SWOT Analysis
14.3 Applied StemCell, Inc.
14.3.1 Company Overview
14.3.2 Role of Applied StemCell, Inc. in the Global CRISPR Gene Editing Market
14.3.3 SWOT Analysis
14.4 Agilent Technologies, Inc.
14.4.1 Company Overview
14.4.2 Role of Agilent Technologies, Inc. in the Global CRISPR Gene Editing Market
14.4.3 Financials
14.4.4 R&D Expenditure, 2017-2019
14.4.5 SWOT Analysis
14.5 Cellecta, Inc.
14.5.1 Company Overview
14.5.2 Role of Cellecta, Inc. in the Global CRISPR Gene Editing Market
14.5.3 SWOT Analysis
14.6 CRISPR Therapeutics AG
14.6.1 Company Overview
14.6.2 Role of CRISPR Therapeutics AG in the Global CRISPR Gene Editing Market
14.6.3 Financials
14.6.4 R&D Expenditure, 2017-2019
14.6.5 SWOT Analysis
14.7 Thermo Fisher Scientific, Inc. INC
14.7.1 Company Overview
14.7.2 Role of Thermo Fisher Scientific, Inc. in the Global CRISPR Gene Editing Market
14.7.3 Financials
14.7.4 R&D Expenditure, 2017-2019
14.7.5 SWOT Analysis
14.8 GeneCopoeia, Inc.
14.8.1 Company Overview
14.8.2 Role of GeneCopoeia, Inc. in the Global CRISPR Gene Editing Market
14.8.3 SWOT Analysis
14.9 GeneScript Biotech Corporation
14.9.1 Company Overview
14.9.2 Role of GenScript Biotech in the Global CRISPR Gene Editing Market
14.9.3 Financials
14.9.4 SWOT Analysis
14.1 Horizon Discovery Group PLC
14.10.1 Company Overview
14.10.2 Role of Horizon Discovery Group PLC in the Global CRISPR Gene Editing Market
14.10.3 Financials
14.10.4 SWOT Analysis
14.11 Integrated DNA Technologies, Inc.
14.11.1 Company Overview
14.11.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market
14.11.3 SWOT Analysis
14.12 Merck KGaA
14.12.1 Company Overview
14.12.2 Role of Merck KGaA in the Global CRISPR Gene Editing Market
14.12.3 Financials
14.12.4 SWOT Analysis
14.13 New England Biolabs, Inc.
14.13.1 Company Overview
14.13.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market
14.13.3 SWOT Analysis
14.14 Origene Technologies, Inc.
14.14.1 Company Overview
14.14.2 Role of Origene Technologies, Inc. in the Global CRISPR Gene Editing Market
14.14.3 SWOT Analysis
14.15 Rockland Immunochemicals, Inc.
14.15.1 Company Overview
14.15.2 Role of Rockland Immunochemicals, Inc. in the Global CRISPR Gene Editing Market
14.15.3 SWOT Analysis
14.16 Synthego Corporation
14.16.1 Company Overview
14.16.2 Role of Synthego Corporation in the Global CRISPR Gene Editing Market
14.16.3 SWOT Analysis
14.17 System Biosciences LLC
14.17.1 Company Overview
14.17.2 Role of System Biosciences LLC in the Global CRISPR Gene Editing Market
14.17.3 SWOT Analysis
14.18 ToolGen, Inc.
14.18.1 Company Overview
14.18.2 Role of ToolGen, Inc. in the Global CRISPR Gene Editing Market
14.18.3 SWOT Analysis
14.19 Takara Bio
14.19.1 Company Overview
14.19.2 Role of Takara Bio in the Global CRISPR Gene Editing Market
14.19.3 Financials
14.19.4 SWOT Analysis
LIST OF TABLES
Table 1: Leading Players in Global CRISPR Gene Editing Market
Table 4.1: CRISPR Exhibits Most Potential as Compared to Other Gene Editing Technologies
Table 5.1: Impact of COVID-19 on CRISPR Clinical Trials
Table 6.1: Private Company Investments in CRISPR Gene Editing
Table 7.1: Total Funding Received and IPO by CRISPR Gene Editing Public Companies
Table 7.2: Funding Scenario of Government Organizations
Table 7.3: Expedited Regulatory Designations Around the World
Table 7.4: Cost of CRISPR Editing Experiment
Table 7.5: Cost of CRISPR Gene Editing
Table 1: Leading Players in Global CRISPR Gene Editing Market
Table 4.1: CRISPR Exhibits Most Potential as Compared to Other Gene Editing Technologies
Table 5.1: Impact of COVID-19 on CRISPR Clinical Trials
Table 6.1: Private Company Investments in CRISPR Gene Editing
Table 7.1: Total Funding Received and IPO by CRISPR Gene Editing Public Companies
Table 7.2: Funding Scenario of Government Organizations
Table 7.3: Expedited Regulatory Designations Around the World
Table 7.4: Cost of CRISPR Editing Experiment
Table 7.5: Cost of CRISPR Gene Editing
LIST OF FIGURES
Figure 1: Global Total Burden of Diseases by Cause
Figure 2: Global Geriatric Population by Age
Figure 3: CRISPR Gene Editing: Potential Areas of Interest
Figure 4: Global CRISPR Gene Editing Market
Figure 5: Global CRISPR Gene Editing Market (by Product Type), $Million, 2019, 2025, and 2030
Figure 6: Global CRISPR Gene Editing: Impact Analysis
Figure 7: Share of Key Developments and Strategies, June 2015-June 2020
Figure 8: Global CRISPR Gene Editing Market (by Product Type), $Million, 2019 and 2030
Figure 9: Global CRISPR Gene Editing Market (by Application), $Million, 2019 and 2030
Figure 10: Global CRISPR Gene Editing Market (by End User), $Million, 2019 and 2030
Figure 11: Global CRISPR Gene Editing Market (by Region), 2019 and 2030
Figure 2.1: Global CRISPR Gene Editing Market Segmentation
Figure 3.1: Global CRISPR Gene Editing Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: CRISPR-Cas Systems and its Classification
Figure 4.2: CRISPR Gene Editing Approach
Figure 4.3: Key Milestones in CRISPR Gene Editing
Figure 4.5: CRISPR Gene Editing Most Potential Future Application Areas
Figure 5.1: CRISPR Gene Editing Clinical Trials (by Phase)
Figure 5.2: Global CRISPR Gene Editing Market, 2019-2030
Figure 5.3: COVID-19 Status Globally
Figure 5.4: COVID-19 Progression Curve
Figure 5.5: Most Impacted Practices in CRISPR Gene Editing
Figure 5.6: COVID-19 Impact on CRISPR Gene Editing Market
Figure 5.7: Application of CRISPR-Cas Systems in COVID-19
Figure 6.1: Global CRISPR Gene Editing: Impact Analysis
Figure 6.2: Rise in CRISPR PubMed Publications During 2012-2017 Expresses Preference Over Other Gene Editing Technologies
Figure 6.3: NIH Funding for CRISPR-Related Research
Figure 6.4: Technological Advancement Using CRISPR Systems
Figure 6.5: Major Ethical Concerns of CRISPR Gene Editing
Figure 6.6: CRISPR Gene Editing Applications in Cell and Gene Therapy
Figure 6.7: Number of Publications on CRISPR Gene Editing in Plant Genome Editing With Agricultural Applications – by Region
Figure 7.1: Top Funded CRISPR Gene Editing Public Companies, 2015-2020
Figure 7.2: Top-Funded CRISPR Gene Editing Private Companies
Figure 7.3: Clinical Trial Authorization for CRISPR Gene Editing
Figure 7.4: Steps for Obtaining Marketing Authorization
Figure 7.5: USFDA Review Timeline
Figure 7.6: EMA Review Timeline
Figure 8.1: Global CRISPR Gene Editing Market Patents (by Application)
Figure 8.2: The U.S. and China Dominated Patents (by Application)
Figure 8.3: Global CRISPR Gene Editing Market Patents (by Region)
Figure 8.4: Global CRISPR Gene Editing Market Patents (by Year)
Figure 9.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 9.2: Revenue Contribution of CRISPR Products Segments, 2020 and 2030
Figure 9.3: Revenue Contribution of Kits and Enzymes Products Segments, 2020 and 2030
Figure 9.4: Global CRISPR Gene Editing Market (Kits and Enzymes), 2019-2030
Figure 9.5: Global CRISPR Gene Editing Market (Vector-Based Cas9), 2019-2030
Figure 9.6: Global CRISPR Gene Editing Market (DNA-Free Cas9), 2019-2030
Figure 9.7: Global CRISPR Gene Editing Market (Libraries), 2019-2030
Figure 9.8: Global CRISPR Gene Editing Market (Design Tools), 2019-2030
Figure 9.9: Global CRISPR Gene Editing Market (Antibodies), 2019-2030
Figure 9.10: Global CRISPR Gene Editing Market (Other Products), 2019-2030
Figure 9.11: Revenue Contribution of CRISPR Services Segments, 2020 and 2030
Figure 9.12: Global CRISPR Gene Editing Market (gRNA Design and Vector Construction), 2019-2030
Figure 9.13: Global CRISPR Gene Editing Market (Cell Line and Engineering), 2019-2030
Figure 9.14: Global CRISPR Gene Editing Market (Screening Services), 2019-2030
Figure 9.15: Global CRISPR Gene Editing Market (Other Services), 2019-2030
Figure 10.1: Revenue Contribution of Different Segments (by Application), 2020 and 2030
Figure 10.2: CRISPR Gene Editing Market (Agriculture), 2019-2030
Figure 10.3: Revenue Contribution of Different Segments (by Biomedical), 2020 and 2030
Figure 10.4: CRISPR Gene Editing Market (Gene Therapy), 2019-2030
Figure 10.5: CRISPR Gene Editing Market (Drug Discovery), 2019-2030
Figure 10.6: CRISPR Gene Editing Market (Diagnostics), 2019-2030
Figure 10.7: CRISPR Gene Editing Market (Industrial), 2019-2030
Figure 10.8: CRISPR Gene Editing Market (Other Applications), 2019-2030
Figure 11.1: Revenue Contribution of End User Segments, 2020 and 2030
Figure 11.2: CRISPR Gene Editing Market (by Academic Institutions and Research Centers), 2019-2030
Figure 11.3: CRISPR Gene Editing Market (by Biotechnology Company), 2019-2030
Figure 11.4: CRISPR Gene Editing Market (by Contract Research Organization), 2019-2030
Figure 11.5: CRISPR Gene Editing Market (by Pharmaceutical and Biopharmaceutical Company), 2019-2030
Figure 12.1: Global CRISPR Gene Editing Market (by Region)
Figure 12.2: Global CRISPR Gene Editing Market (by Region), 2019-2030
Figure 12.3: Global CRISPR Gene Editing Market (by Region), 2019-2030
Figure 12.4: North America CRISPR Gene Editing Market, 2019-2030
Figure 12.5: North America: Market Dynamics
Figure 12.6: Revenue Contributions of Various Countries in North America, 2019 and 2030
Figure 12.7: U.S. CRISPR Gene Editing Market, 2019-2030
Figure 12.8: U.S. CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.9: Canada CRISPR Gene Editing Market, 2019-2030
Figure 12.10: Canada CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.11: Europe CRISPR Gene Editing Market, 2019-2030
Figure 12.12: Europe: Market Dynamics
Figure 12.13: Revenue Contributions of Various Countries in Europe, 2019 and 2030
Figure 12.14: U.K. CRISPR Gene Editing Market, 2019-2030
Figure 12.15: U.K. CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.16: Germany CRISPR Gene Editing Market, 2019-2030
Figure 12.17: Germany CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.18: France CRISPR Gene Editing Market, 2019-2030
Figure 12.19: France CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.20: Spain CRISPR Gene Editing Market, 2019-2030
Figure 12.21: Spain CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.22: Italy CRISPR Gene Editing Market, 2019-2030
Figure 12.23: Italy CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.24: Switzerland CRISPR Gene Editing Market, 2019-2030
Figure 12.25: Switzerland CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.26: Rest-of-Europe CRISPR Gene Editing Market, 2019-2030
Figure 12.27: Rest-of-Europe CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.28: Asia-Pacific CRISPR Gene Editing Market, 2019-2030
Figure 12.29: Asia-Pacific: Market Dynamics
Figure 12.30: Revenue Contributions of Various Countries in Asia-Pacific, 2019 and 2030
Figure 12.31: Japan CRISPR Gene Editing Market, 2019-2030
Figure 12.32: Japan CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.33: China CRISPR Gene Editing Market, 2019-2030
Figure 12.34: China CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.35: South Korea CRISPR Gene Editing Market, 2019-2030
Figure 12.36: South Korea CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.37: Singapore CRISPR Gene Editing Market, 2019-2030
Figure 12.38: Singapore CRISPR gene editing Market (by Application), 2019-2030
Figure 12.39: Australia CRISPR Gene Editing Market, 2019-2030
Figure 12.40: Australia CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.41: Australia CRISPR Gene Editing Market, 2019-2030
Figure 12.42: India CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.43: Rest-of-APAC CRISPR Gene Editing Market, 2019-2030
Figure 12.44: Rest-of-APAC CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.45: Latin America CRISPR Gene Editing Market, 2019-2030
Figure 12.46: Latin America: Market Dynamics
Figure 12.47: Revenue Contributions of Various Countries in Latin America, 2019 and 2030
Figure 12.48: Brazil CRISPR Gene Editing Market, 2019-2030
Figure 12.49: Brazil CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.50: Mexico CRISPR Gene Editing Market, 2019-2030
Figure 12.51: Mexico CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.52: RoLA CRISPR Gene Editing Market, 2019-2030
Figure 12.53: RoLA CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.54: RoW CRISPR Gene Editing market, 2019-2030
Figure 12.55: RoW CRISPR Gene Editing Market (by Application), 2019-2030
Figure 13.1: Share of Key Developments and Strategies, July 2015-July 2020
Figure 13.2: Regulatory and Legal Developments Share (by Company), July 2015-July 2020
Figure 13.3: Synergistic Activities (by Company), July 2015-July 2020
Figure 13.4: Company Share (by Synergistic Activity), July 2015-July 2020
Figure 13.5: M&A Activities Share (by Company), July 2015-July 2020
Figure 13.6: Funding Activities (by Company), July 2015-July 2020
Figure 13.7: Market Share Analysis (by Company), 2018 and 2019
Figure 13.8: Growth Share Matrix for Global CRISPR Gene Editing Market (by Company), 2019
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Abcam, Inc.: Overall Product Portfolio
Figure 14.3: Abcam, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.4: Abcam, Inc.: Overall Financials, 2017-2019
Figure 14.5: Abcam, Inc. Net Revenue (by Business Segment), 2017-2019
Figure 14.6: Abcam, Inc. (by Region), 2017-2019
Figure 14.7: Abcam, Inc. R&D Expense, 2017-2019
Figure 14.8: Abcam, Inc.: SWOT Analysis
Figure 14.9: Applied StemCell, Inc.: Overall Product Portfolio
Figure 14.10: Applied StemCell, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.11: Applied StemCell, Inc.: SWOT Analysis
Figure 14.12: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 14.13: Agilent Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.14: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.15: Agilent Technologies, Inc. Net Revenue (by Business Segment), 2017-2019
Figure 14.16: Agilent Technologies, Inc. (by Region), 2017-2019
Figure 14.17: Agilent Technologies, Inc. R&D Expense, 2017-2019
Figure 14.18: Abcam, Inc.: SWOT Analysis
Figure 14.19: Cellecta, Inc.: Overall Product Portfolio
Figure 14.20: Cellecta, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.21: Cellecta, Inc.: SWOT Analysis
Figure 14.22: CRISPR Therapeutics: Overall Product Portfolio
Figure 14.23: CRISPR Therapeutics: CRISPR Gene Editing Product Portfolio Pipeline
Figure 14.24: CRISPR Therapeutics: Overall Financials, 2017-2019
Figure 14.25: CRISPR Therapeutics AGR&D Expenditure, 2017-2019
Figure 14.26: CRISPR Therapeutics: SWOT Analysis
Figure 14.27: Thermo Fisher Scientific, Inc.: Overall Product Portfolio
Figure 14.28: Thermo Fisher Scientific, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.29: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 14.30: Thermo Fisher Scientific, Inc. Net Revenue (by Business Segment), 2017-2019
Figure 14.31: Thermo Fisher Scientific, Inc. Net Revenue (by Region), 2017-2019
Figure 14.32: Thermo Fisher Scientific, Inc.: R&D Expense, 2017-2019
Figure 14.33: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 14.34: GeneCopoeia, Inc.: Overall Product Portfolio
Figure 14.35: GeneCopoeia, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.36: GeneCopoeia, Inc.: SWOT Analysis
Figure 14.37: GeneScript Biotech: Overall Product Portfolio
Figure 14.38: GenScript Biotech: CRISPR Gene Editing Product Portfolio Category
Figure 14.39: GenScript Biotech: Overall Financials, 2017-2019
Figure 14.40: GenScript Net Revenue (by Business Segment), 2017-2019
Figure 14.41: GenScript Biotech Net Revenue (by Region), 2017-2019
Figure 14.42: GenScript Biotech: R&D Expense, 2017-2019
Figure 14.43: GenScript Biotech: SWOT Analysis
Figure 14.44: Horizon Discovery Group PLC: Overall Product Portfolio
Figure 14.45: Horizon Discovery Group PLC: CRISPR Gene Editing Product Portfolio Category
Figure 14.46: Horizon Discovery Group PLC: Overall Financials, 2017-2019
Figure 14.47: Horizon Discovery Group PLC Net Revenue (by Business Segment), 2017-2019
Figure 14.48: Horizon Discovery Group PLC Net Revenue (by Region), 2017-2019
Figure 14.49: Horizon Discovery Group PLC: R&D Expense, 2017-2019
Figure 14.50: Horizon Discovery Group PLC: SWOT Analysis
Figure 14.51: Integrated DNA Technologies, Inc.: Overall Product Portfolio
Figure 14.52: Integrated DNA Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.53: Integrated DNA Technologies, Inc.: SWOT Analysis
Figure 14.54: Merck KGaA: Overall Product Portfolio
Figure 14.55: Merck KGaA: CRISPR Gene Editing Product Portfolio Category
Figure 14.56: Merck KGaA: Overall Financials, 2017-2019
Figure 14.57: Merck KGaA Net Revenue (by Business Segment), 2017-2019
Figure 14.58: Merck KGaA Net Revenue (by Region), 2017-2019
Figure 14.59: Merck KGaA: R&D Expense, 2017-2019
Figure 14.60: Merck KGaA: SWOT Analysis
Figure 14.61: New England Biolabs, Inc.: Overall Product Portfolio
Figure 14.62: New England Biolabs, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.63: New England Biolabs, Inc.: SWOT Analysis
Figure 14.64: Origene Technologies, Inc.: Overall Product Portfolio
Figure 14.65: Origene Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.66: Origene Technologies, Inc.: SWOT Analysis
Figure 14.67: Rockland Immunochemicals, Inc.: Overall Product Portfolio
Figure 14.68: Rockland Immunochemicals, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.69: Rockland Immunochemicals, Inc.: SWOT Analysis
Figure 14.70: Synthego Corporation: Overall Product Portfolio
Figure 14.71: Synthego Corporation: CRISPR Gene Editing Product Portfolio Category
Figure 14.72: Synthego Corporation: SWOT Analysis
Figure 14.73: System Biosciences LLC: Overall Product Portfolio
Figure 14.74: System Biosciences LLC: CRISPR Gene Editing Product Portfolio Category
Figure 14.75: System Biosciences LLC: SWOT Analysis
Figure 14.76: ToolGen, Inc.: Overall Product Portfolio
Figure 14.77: ToolGen, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.78: ToolGen, Inc.: SWOT Analysis
Figure 14.79: Takara Bio: Overall Product Portfolio
Figure 14.80: Takara Bio: CRISPR Gene Editing Product Portfolio Category
Figure 14.81: Takara Bio: Overall Financials, 2017-2019
Figure 14.82: Takara Bio Net Revenue (by Business Segment), 2017-2019
Figure 14.83: Takara Bio Net Revenue (by Region), 2017-2019
Figure 14.84: Takara Bio: R&D Expense, 2017-2019
Figure 14.85: Takara Bio: SWOT Analysis
Figure 1: Global Total Burden of Diseases by Cause
Figure 2: Global Geriatric Population by Age
Figure 3: CRISPR Gene Editing: Potential Areas of Interest
Figure 4: Global CRISPR Gene Editing Market
Figure 5: Global CRISPR Gene Editing Market (by Product Type), $Million, 2019, 2025, and 2030
Figure 6: Global CRISPR Gene Editing: Impact Analysis
Figure 7: Share of Key Developments and Strategies, June 2015-June 2020
Figure 8: Global CRISPR Gene Editing Market (by Product Type), $Million, 2019 and 2030
Figure 9: Global CRISPR Gene Editing Market (by Application), $Million, 2019 and 2030
Figure 10: Global CRISPR Gene Editing Market (by End User), $Million, 2019 and 2030
Figure 11: Global CRISPR Gene Editing Market (by Region), 2019 and 2030
Figure 2.1: Global CRISPR Gene Editing Market Segmentation
Figure 3.1: Global CRISPR Gene Editing Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: CRISPR-Cas Systems and its Classification
Figure 4.2: CRISPR Gene Editing Approach
Figure 4.3: Key Milestones in CRISPR Gene Editing
Figure 4.5: CRISPR Gene Editing Most Potential Future Application Areas
Figure 5.1: CRISPR Gene Editing Clinical Trials (by Phase)
Figure 5.2: Global CRISPR Gene Editing Market, 2019-2030
Figure 5.3: COVID-19 Status Globally
Figure 5.4: COVID-19 Progression Curve
Figure 5.5: Most Impacted Practices in CRISPR Gene Editing
Figure 5.6: COVID-19 Impact on CRISPR Gene Editing Market
Figure 5.7: Application of CRISPR-Cas Systems in COVID-19
Figure 6.1: Global CRISPR Gene Editing: Impact Analysis
Figure 6.2: Rise in CRISPR PubMed Publications During 2012-2017 Expresses Preference Over Other Gene Editing Technologies
Figure 6.3: NIH Funding for CRISPR-Related Research
Figure 6.4: Technological Advancement Using CRISPR Systems
Figure 6.5: Major Ethical Concerns of CRISPR Gene Editing
Figure 6.6: CRISPR Gene Editing Applications in Cell and Gene Therapy
Figure 6.7: Number of Publications on CRISPR Gene Editing in Plant Genome Editing With Agricultural Applications – by Region
Figure 7.1: Top Funded CRISPR Gene Editing Public Companies, 2015-2020
Figure 7.2: Top-Funded CRISPR Gene Editing Private Companies
Figure 7.3: Clinical Trial Authorization for CRISPR Gene Editing
Figure 7.4: Steps for Obtaining Marketing Authorization
Figure 7.5: USFDA Review Timeline
Figure 7.6: EMA Review Timeline
Figure 8.1: Global CRISPR Gene Editing Market Patents (by Application)
Figure 8.2: The U.S. and China Dominated Patents (by Application)
Figure 8.3: Global CRISPR Gene Editing Market Patents (by Region)
Figure 8.4: Global CRISPR Gene Editing Market Patents (by Year)
Figure 9.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 9.2: Revenue Contribution of CRISPR Products Segments, 2020 and 2030
Figure 9.3: Revenue Contribution of Kits and Enzymes Products Segments, 2020 and 2030
Figure 9.4: Global CRISPR Gene Editing Market (Kits and Enzymes), 2019-2030
Figure 9.5: Global CRISPR Gene Editing Market (Vector-Based Cas9), 2019-2030
Figure 9.6: Global CRISPR Gene Editing Market (DNA-Free Cas9), 2019-2030
Figure 9.7: Global CRISPR Gene Editing Market (Libraries), 2019-2030
Figure 9.8: Global CRISPR Gene Editing Market (Design Tools), 2019-2030
Figure 9.9: Global CRISPR Gene Editing Market (Antibodies), 2019-2030
Figure 9.10: Global CRISPR Gene Editing Market (Other Products), 2019-2030
Figure 9.11: Revenue Contribution of CRISPR Services Segments, 2020 and 2030
Figure 9.12: Global CRISPR Gene Editing Market (gRNA Design and Vector Construction), 2019-2030
Figure 9.13: Global CRISPR Gene Editing Market (Cell Line and Engineering), 2019-2030
Figure 9.14: Global CRISPR Gene Editing Market (Screening Services), 2019-2030
Figure 9.15: Global CRISPR Gene Editing Market (Other Services), 2019-2030
Figure 10.1: Revenue Contribution of Different Segments (by Application), 2020 and 2030
Figure 10.2: CRISPR Gene Editing Market (Agriculture), 2019-2030
Figure 10.3: Revenue Contribution of Different Segments (by Biomedical), 2020 and 2030
Figure 10.4: CRISPR Gene Editing Market (Gene Therapy), 2019-2030
Figure 10.5: CRISPR Gene Editing Market (Drug Discovery), 2019-2030
Figure 10.6: CRISPR Gene Editing Market (Diagnostics), 2019-2030
Figure 10.7: CRISPR Gene Editing Market (Industrial), 2019-2030
Figure 10.8: CRISPR Gene Editing Market (Other Applications), 2019-2030
Figure 11.1: Revenue Contribution of End User Segments, 2020 and 2030
Figure 11.2: CRISPR Gene Editing Market (by Academic Institutions and Research Centers), 2019-2030
Figure 11.3: CRISPR Gene Editing Market (by Biotechnology Company), 2019-2030
Figure 11.4: CRISPR Gene Editing Market (by Contract Research Organization), 2019-2030
Figure 11.5: CRISPR Gene Editing Market (by Pharmaceutical and Biopharmaceutical Company), 2019-2030
Figure 12.1: Global CRISPR Gene Editing Market (by Region)
Figure 12.2: Global CRISPR Gene Editing Market (by Region), 2019-2030
Figure 12.3: Global CRISPR Gene Editing Market (by Region), 2019-2030
Figure 12.4: North America CRISPR Gene Editing Market, 2019-2030
Figure 12.5: North America: Market Dynamics
Figure 12.6: Revenue Contributions of Various Countries in North America, 2019 and 2030
Figure 12.7: U.S. CRISPR Gene Editing Market, 2019-2030
Figure 12.8: U.S. CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.9: Canada CRISPR Gene Editing Market, 2019-2030
Figure 12.10: Canada CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.11: Europe CRISPR Gene Editing Market, 2019-2030
Figure 12.12: Europe: Market Dynamics
Figure 12.13: Revenue Contributions of Various Countries in Europe, 2019 and 2030
Figure 12.14: U.K. CRISPR Gene Editing Market, 2019-2030
Figure 12.15: U.K. CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.16: Germany CRISPR Gene Editing Market, 2019-2030
Figure 12.17: Germany CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.18: France CRISPR Gene Editing Market, 2019-2030
Figure 12.19: France CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.20: Spain CRISPR Gene Editing Market, 2019-2030
Figure 12.21: Spain CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.22: Italy CRISPR Gene Editing Market, 2019-2030
Figure 12.23: Italy CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.24: Switzerland CRISPR Gene Editing Market, 2019-2030
Figure 12.25: Switzerland CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.26: Rest-of-Europe CRISPR Gene Editing Market, 2019-2030
Figure 12.27: Rest-of-Europe CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.28: Asia-Pacific CRISPR Gene Editing Market, 2019-2030
Figure 12.29: Asia-Pacific: Market Dynamics
Figure 12.30: Revenue Contributions of Various Countries in Asia-Pacific, 2019 and 2030
Figure 12.31: Japan CRISPR Gene Editing Market, 2019-2030
Figure 12.32: Japan CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.33: China CRISPR Gene Editing Market, 2019-2030
Figure 12.34: China CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.35: South Korea CRISPR Gene Editing Market, 2019-2030
Figure 12.36: South Korea CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.37: Singapore CRISPR Gene Editing Market, 2019-2030
Figure 12.38: Singapore CRISPR gene editing Market (by Application), 2019-2030
Figure 12.39: Australia CRISPR Gene Editing Market, 2019-2030
Figure 12.40: Australia CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.41: Australia CRISPR Gene Editing Market, 2019-2030
Figure 12.42: India CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.43: Rest-of-APAC CRISPR Gene Editing Market, 2019-2030
Figure 12.44: Rest-of-APAC CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.45: Latin America CRISPR Gene Editing Market, 2019-2030
Figure 12.46: Latin America: Market Dynamics
Figure 12.47: Revenue Contributions of Various Countries in Latin America, 2019 and 2030
Figure 12.48: Brazil CRISPR Gene Editing Market, 2019-2030
Figure 12.49: Brazil CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.50: Mexico CRISPR Gene Editing Market, 2019-2030
Figure 12.51: Mexico CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.52: RoLA CRISPR Gene Editing Market, 2019-2030
Figure 12.53: RoLA CRISPR Gene Editing Market (by Application), 2019-2030
Figure 12.54: RoW CRISPR Gene Editing market, 2019-2030
Figure 12.55: RoW CRISPR Gene Editing Market (by Application), 2019-2030
Figure 13.1: Share of Key Developments and Strategies, July 2015-July 2020
Figure 13.2: Regulatory and Legal Developments Share (by Company), July 2015-July 2020
Figure 13.3: Synergistic Activities (by Company), July 2015-July 2020
Figure 13.4: Company Share (by Synergistic Activity), July 2015-July 2020
Figure 13.5: M&A Activities Share (by Company), July 2015-July 2020
Figure 13.6: Funding Activities (by Company), July 2015-July 2020
Figure 13.7: Market Share Analysis (by Company), 2018 and 2019
Figure 13.8: Growth Share Matrix for Global CRISPR Gene Editing Market (by Company), 2019
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Abcam, Inc.: Overall Product Portfolio
Figure 14.3: Abcam, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.4: Abcam, Inc.: Overall Financials, 2017-2019
Figure 14.5: Abcam, Inc. Net Revenue (by Business Segment), 2017-2019
Figure 14.6: Abcam, Inc. (by Region), 2017-2019
Figure 14.7: Abcam, Inc. R&D Expense, 2017-2019
Figure 14.8: Abcam, Inc.: SWOT Analysis
Figure 14.9: Applied StemCell, Inc.: Overall Product Portfolio
Figure 14.10: Applied StemCell, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.11: Applied StemCell, Inc.: SWOT Analysis
Figure 14.12: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 14.13: Agilent Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.14: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.15: Agilent Technologies, Inc. Net Revenue (by Business Segment), 2017-2019
Figure 14.16: Agilent Technologies, Inc. (by Region), 2017-2019
Figure 14.17: Agilent Technologies, Inc. R&D Expense, 2017-2019
Figure 14.18: Abcam, Inc.: SWOT Analysis
Figure 14.19: Cellecta, Inc.: Overall Product Portfolio
Figure 14.20: Cellecta, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.21: Cellecta, Inc.: SWOT Analysis
Figure 14.22: CRISPR Therapeutics: Overall Product Portfolio
Figure 14.23: CRISPR Therapeutics: CRISPR Gene Editing Product Portfolio Pipeline
Figure 14.24: CRISPR Therapeutics: Overall Financials, 2017-2019
Figure 14.25: CRISPR Therapeutics AGR&D Expenditure, 2017-2019
Figure 14.26: CRISPR Therapeutics: SWOT Analysis
Figure 14.27: Thermo Fisher Scientific, Inc.: Overall Product Portfolio
Figure 14.28: Thermo Fisher Scientific, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.29: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 14.30: Thermo Fisher Scientific, Inc. Net Revenue (by Business Segment), 2017-2019
Figure 14.31: Thermo Fisher Scientific, Inc. Net Revenue (by Region), 2017-2019
Figure 14.32: Thermo Fisher Scientific, Inc.: R&D Expense, 2017-2019
Figure 14.33: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 14.34: GeneCopoeia, Inc.: Overall Product Portfolio
Figure 14.35: GeneCopoeia, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.36: GeneCopoeia, Inc.: SWOT Analysis
Figure 14.37: GeneScript Biotech: Overall Product Portfolio
Figure 14.38: GenScript Biotech: CRISPR Gene Editing Product Portfolio Category
Figure 14.39: GenScript Biotech: Overall Financials, 2017-2019
Figure 14.40: GenScript Net Revenue (by Business Segment), 2017-2019
Figure 14.41: GenScript Biotech Net Revenue (by Region), 2017-2019
Figure 14.42: GenScript Biotech: R&D Expense, 2017-2019
Figure 14.43: GenScript Biotech: SWOT Analysis
Figure 14.44: Horizon Discovery Group PLC: Overall Product Portfolio
Figure 14.45: Horizon Discovery Group PLC: CRISPR Gene Editing Product Portfolio Category
Figure 14.46: Horizon Discovery Group PLC: Overall Financials, 2017-2019
Figure 14.47: Horizon Discovery Group PLC Net Revenue (by Business Segment), 2017-2019
Figure 14.48: Horizon Discovery Group PLC Net Revenue (by Region), 2017-2019
Figure 14.49: Horizon Discovery Group PLC: R&D Expense, 2017-2019
Figure 14.50: Horizon Discovery Group PLC: SWOT Analysis
Figure 14.51: Integrated DNA Technologies, Inc.: Overall Product Portfolio
Figure 14.52: Integrated DNA Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.53: Integrated DNA Technologies, Inc.: SWOT Analysis
Figure 14.54: Merck KGaA: Overall Product Portfolio
Figure 14.55: Merck KGaA: CRISPR Gene Editing Product Portfolio Category
Figure 14.56: Merck KGaA: Overall Financials, 2017-2019
Figure 14.57: Merck KGaA Net Revenue (by Business Segment), 2017-2019
Figure 14.58: Merck KGaA Net Revenue (by Region), 2017-2019
Figure 14.59: Merck KGaA: R&D Expense, 2017-2019
Figure 14.60: Merck KGaA: SWOT Analysis
Figure 14.61: New England Biolabs, Inc.: Overall Product Portfolio
Figure 14.62: New England Biolabs, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.63: New England Biolabs, Inc.: SWOT Analysis
Figure 14.64: Origene Technologies, Inc.: Overall Product Portfolio
Figure 14.65: Origene Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.66: Origene Technologies, Inc.: SWOT Analysis
Figure 14.67: Rockland Immunochemicals, Inc.: Overall Product Portfolio
Figure 14.68: Rockland Immunochemicals, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.69: Rockland Immunochemicals, Inc.: SWOT Analysis
Figure 14.70: Synthego Corporation: Overall Product Portfolio
Figure 14.71: Synthego Corporation: CRISPR Gene Editing Product Portfolio Category
Figure 14.72: Synthego Corporation: SWOT Analysis
Figure 14.73: System Biosciences LLC: Overall Product Portfolio
Figure 14.74: System Biosciences LLC: CRISPR Gene Editing Product Portfolio Category
Figure 14.75: System Biosciences LLC: SWOT Analysis
Figure 14.76: ToolGen, Inc.: Overall Product Portfolio
Figure 14.77: ToolGen, Inc.: CRISPR Gene Editing Product Portfolio Category
Figure 14.78: ToolGen, Inc.: SWOT Analysis
Figure 14.79: Takara Bio: Overall Product Portfolio
Figure 14.80: Takara Bio: CRISPR Gene Editing Product Portfolio Category
Figure 14.81: Takara Bio: Overall Financials, 2017-2019
Figure 14.82: Takara Bio Net Revenue (by Business Segment), 2017-2019
Figure 14.83: Takara Bio Net Revenue (by Region), 2017-2019
Figure 14.84: Takara Bio: R&D Expense, 2017-2019
Figure 14.85: Takara Bio: SWOT Analysis
